Alphabet unit halts glucose-detecting contact lens project

Alphabet unit halts glucose-detecting contact lens project

  • November 18, 2018
Table of Contents

Alphabet unit halts glucose-detecting contact lens project

Alphabet Inc’s life sciences division Verily said on Friday that it was putting on hold one of its oldest and highest-profile projects, a smart contact lens designed to help monitor sugar levels. The project, started in 2014, aimed to help diabetics better manage their blood sugar levels by embedding sensors on a contact lens to monitor the glucose levels in their tears. In a blog update, Verily cited here insufficient consistency in the correlation between tear glucose and blood glucose concentrations to support the requirements of a medical device.

Verily, which was previously part of the tech firm’s Google X research and development unit, had partnered with Novartis’ eye-care division, Alcon, to develop the lens.

Source: reuters.com

Tags :
Share :
comments powered by Disqus

Related Posts

‘Ground-breaking’ diabetes insulin drug trialled in Cardiff

‘Ground-breaking’ diabetes insulin drug trialled in Cardiff

A ‘ground-breaking’ drug that helps people with diabetes re-grow insulin-making cells has been developed. About 19,000 people live with Type 1 of the condition in Wales and 90% have less than 5% of these cells left. This means they have to inject insulin

Read More
Report: billionaire Sackler family, accused of encouraging the opioid epidemic

Report: billionaire Sackler family, accused of encouraging the opioid epidemic

Read More
A cure for cancer: how to kill a killer

A cure for cancer: how to kill a killer

Last month, the Nobel prize in medicine was awarded for two breakthrough scientific discoveries heralded as having “revolutionised cancer treatment”, and “fundamentally changed the way we view how cancer can be managed”. One of them went to a charismatic, harmonica-playing Texan named Jim Allison for his breakthrough advances in cancer immunotherapy. His discovery had resulted in transformative outcomes for cancer patients and a radical new direction for cancer research.

Read More